tbResList Print

Product

EGCG EGCG (Epigallocatechin Gallate)

Description: Epigallocatechin-3-gallate — EGCG is a naturally occurring galloylated flavan-3-ol and the quantitatively dominant catechin in green tea leaves from Camellia sinensis. It is formally classified as a dietary polyphenol, catechin and investigational pleiotropic bioactive compound. EGCG has concentration-, oxidation-, metal- and cellular-context-dependent activity: it can function as an antioxidant and NRF2-associated cytoprotective agent in normal tissues, but may generate reactive oxygen species and induce stress-mediated death in susceptible cancer cells. It is not an approved anticancer drug, and purified high-dose extracts are pharmacologically and toxicologically distinct from brewed green tea.

Primary mechanisms (ranked):
<ol>
<li>Biphasic redox modulation, including direct radical scavenging and metal chelation at lower exposure, but auto-oxidation, hydrogen-peroxide generation and pro-oxidant stress under permissive cancer-cell culture conditions.</li>
<li>Suppression of proliferative and survival signalling, particularly PI3K–AKT–mTOR, NF-κB, receptor tyrosine kinase, STAT and context-dependent MAPK pathways.</li>
<li>Mitochondrial dysfunction and intrinsic apoptosis through mitochondrial membrane-potential loss, cytochrome-c release and caspase activation.</li>
<li>Cell-cycle arrest through modulation of cyclins, cyclin-dependent kinases, p21, p27 and p53-associated signalling.</li>
<li>Inhibition of invasion, epithelial–mesenchymal transition and extracellular-matrix degradation through reduced FAK, MMP-2, MMP-9, uPA and related motility pathways.</li>
<li>Suppression of HIF-1α–VEGF signalling, angiogenesis and hypoxia adaptation.</li>
<li>Metabolic disruption involving reduced glycolysis, glucose transport and context-dependent mitochondrial energy production.</li>
<li>Epigenetic modulation, including experimental inhibition or altered expression of DNMTs, HDACs and EZH2.</li>
<li>Modulation of proteostasis, autophagy, endoplasmic-reticulum stress and unfolded-protein responses.</li>
<li>NRF2 activation as a secondary adaptive mechanism, generally cytoprotective in normal cells but potentially protective or treatment-resistant in some cancers.</li>
<li>Chemosensitization or radiosensitization in selected experimental models; treatment protection, antagonism or normal-tissue radioprotection can also occur depending on dose, schedule and therapy.</li>
</ol>

Bioavailability / PK relevance: Oral bioavailability is low and highly variable because EGCG is chemically unstable near neutral or alkaline pH, has limited intestinal permeability, undergoes extensive methylation, glucuronidation and sulfation, and is influenced by food and microbiota. Plasma concentrations after tea consumption are usually submicromolar, while large supplemental doses may transiently produce low-micromolar exposure. Fasting can increase systemic exposure but may also increase hepatic toxicity risk. Nanoencapsulation, lipid carriers and other delivery systems improve exposure experimentally but are not established anticancer treatments.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100 µM EGCG, whereas conventional oral administration generally produces submicromolar to low-micromolar plasma concentrations. Thus, many direct cytotoxic, glycolytic, mitochondrial and kinase effects occur at concentrations substantially exceeding typical achievable systemic exposure. EGCG can also oxidize in culture media and generate extracellular hydrogen peroxide, creating experimental effects that may not translate directly in vivo.

Clinical evidence status: Extensive preclinical evidence; multiple small human biomarker, prevention and early-phase studies; limited randomized evidence for selected premalignant or recurrence-prevention settings; no established therapeutic efficacy against active cancer and no regulatory approval as an anticancer agent. A recent randomized colorectal adenoma study reported reduced recurrence, but this does not establish treatment efficacy for invasive colorectal cancer. Ongoing clinical studies continue to investigate prevention and adjunctive applications.

Safety and interactions: Brewed green tea is generally well tolerated, whereas concentrated green-tea extracts and purified EGCG have been associated with dose-dependent aminotransferase elevations and rare clinically significant liver injury. Doses around 800 mg EGCG per day have generated a regulatory safety signal, and a universally safe supplemental dose has not been established. Risk may be higher with fasting administration, pre-existing liver disease or multi-ingredient weight-loss products. EGCG can bind non-heme iron, alter drug transporters or metabolic enzymes, and modify exposure to some medications; oncology use should therefore be reviewed for drug-specific interactions.

 

<a href="https://www.medicinenet.com/egcg_epigallocatechin_gallate_benefits_dosage/article.htm">
EGCG (Epigallocatechin Gallate) is found in green tea. 100 times more effective than Vitamin C and 25 times more effective than Vitamin E at protecting cells from damage associated with oxidative stress. </a> 
EGCG Epigallocatechin Gallate (Green Tea) -Catechin 
Summary: 
1. Concentration is a factor that could determine whether green tea polyphenols act as antioxidants or pro-oxidants. 
2. Poor bioavailability: taking EGCG capsules without food was better. 
3. Cancer dosage 4g/day (2g twice per day)? with curcumin may help (another ref says 700–2100 mg/d). FDA says <800mg/day (hepatotoxicity) 
4. EGCG is susceptible to oxidative degradation. 
5. “As for the pH level, the acidic environments enhance the stability of EGCG”. 
6. “EGCG may enhance nanoparticle uptake by tumor cells” 
7. Might be iron chelator (removing iron from cancer cells) 
8. Claimed as synergistic effect with chemotherapy ( cisplatin, bleomycin, gemcitabine. 
9. May suppress glucose metabolism, interfere with VEGF, downregulate NF-κB and MMP-9, down-regulation of androgen-regulated miRNA-21. 
10. Take with red pepper powder, Capsicum ratio 25:1 (based on half life, they did every 4 hr) (chili pepper vanilloid capsaicin). 
11. EGCG mediated ROS formation can upregulate CTR1 expression via the ERK1/2/NEAT1 pathway, which can increase the intake of chemotherapeutic drugs such as cisplatin in NSCLC cells and act as a chemosensitizer [58] 
12. Matcha green tea has highest EGCG (2-3X) because consuming leaf. 
13. EGCG is an ENOX2 inhibitor. 
14. Nrf2 activator in both cancer and normal cells. This
<a href="https://nestronics.ca/dbx/tbResEdit.php?rid=3212"> example</a>
of lung cancer show both directions in different cell lines, but both toward optimim level.
 
Biological activity, EGCG has been reported to exhibit a range of effects, including: 
 Antioxidant activity: 10-50 μM 
 Anti-inflammatory activity: 20-50 μM 
 Anticancer activity: 50-100 μM 
 Cardiovascular health: 20-50 μM 
 Neuroprotective activity: 10-50 μM 
 
Drinking a cup (or two cups) of green tea (in which one might ingest roughly 50–100 mg of EGCG from brewed tea) generally results in peak plasma EGCG concentrations in the range of approximately 0.1 to 0.6 μM. 
 
With higher, supplement-type doses (e.g., oral doses in the 500 mg–800 mg range that are sometimes studied for clinical benefits), peak plasma concentrations in humans can reach the low micromolar range, often reported around ~1–2 μM and in some cases up to 5 μM. 
 
Reported values can range from about 25–50 mg of EGCG per gram of matcha powder. 
In cases where the matcha is exceptionally catechin-rich, the content could reach 200–250 mg or more in 5 g. 
 
-Peak plasma concentration roughly 1 to 2 hours after oral ingestion. 
-Elimination half-life of EGCG in plasma is commonly reported to be in the range of about 3 to 5 hours. 
 
Supplemental EGCG 
Dose (mg) ≈ Peak Plasma EGCG (µM) 
~50 mg ≈ 0.1–0.3 µM 
~100 mg ≈ 0.2–0.6 µM 
~250 mg ≈ 0.5–1.0 µM 
~500 mg ≈ 1–2 µM 
~800 mg or higher ≈ 1–5 µM 
 
50mg of EGCG in 1g of matcha tea(1/2 teaspoon) 
 
Studies on green tea extracts have employed doses roughly equivalent to 300–800 mg/day of EGCG. Excessive doses can cause liver toxicity in some cases. 
 
Methods to improve bioavailability 
-Lipid-based carriers or nanoemulsions 
-Polymer-based nanoparticles or encapsulation 
-Co-administration with ascorbic acid (vitamin C) 
-Co-administration of adjuvants like piperine (perhaps sunflower lecithin and chitosan)
-Using multiple smaller doses rather than one large single dose. 
-Taking EGCG on an empty stomach or under fasting conditions, or aligning dosing with optimal pH conditions in the GI tract, may improve its absorption.(acidic environment is generally more favorable for its stability and absorption). 
– EGCG is more stable under acidic conditions. In the stomach, where the pH is typically around 1.5 to 3.5, EGCG is less prone to degradation compared to the more neutral or basic environments of the small intestine. 
- At neutral (around pH 7) or alkaline pH, EGCG undergoes auto-oxidation, reducing the effective concentration available for absorption. 
– Although the stomach’s acidic pH helps maintain EGCG’s stability, most absorption occurs in the small intestine, where the pH is closer to neutral. 
– To counterbalance the inherent instability in the intestine, strategies such as co-administration of pH-modifying agents (like vitamin C) are sometimes used. These agents help to maintain a slightly acidic environment in the gut microenvironment, potentially improving EGCG stability during its transit and absorption. 
– The use of acidifiers or buffering agents in supplements may help preserve EGCG until it reaches the absorption sites. 

 
-Note <a href="tbResList.php?qv=73&tsv=1109&wNotes=on&exSp=open">half-life</a> 3–5 hours. 
- low <a href="tbResList.php?qv=73&tsv=792&wNotes=on&exSp=open">BioAv</a> 1%? despite its limited absorption, it is rapidly disseminated throughout the body
 
Pathways: 


- induce
<a href="tbResList.php?qv=73&tsv=275&wNotes=on">ROS</a> production 
- ROS↑ related:
<a href="tbResList.php?qv=73&tsv=197&wNotes=on&word=MMP↓">MMP↓</a>(ΔΨm),
<a href="tbResList.php?qv=73&tsv=103&wNotes=on">ER Stress↑</a>,
<a href="tbResList.php?qv=73&tsv=459&wNotes=on">UPR↑</a>,
<a href="tbResList.php?qv=73&tsv=356&wNotes=on">GRP78↑</a>,
<a href="tbResList.php?qv=73&tsv=38&wNotes=on&word=Ca+2↑">Ca+2↑</a>,
<a href="tbResList.php?qv=73&tsv=77&wNotes=on">Cyt‑c↑</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=Casp">Caspases↑</a>,
<a href="tbResList.php?qv=73&tsv=82&wNotes=on&word=DNAdam↑">DNA damage↑</a>,
<a href="tbResList.php?qv=73&tsv=239&wNotes=on">cl-PARP↑</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=HSP">HSP↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=Prx">Prx</a>,

 


- Does NOT Lower AntiOxidant defense in Cancer Cells:
<a href="tbResList.php?qv=73&tsv=226&wNotes=on&word=NRF2↑">NRF2↑</a>,
<a href="tbResList.php?qv=73&word=Trx&wNotes=on">TrxR↓**</a>,
<a href="tbResList.php?qv=73&tsv=298&wNotes=on&word=SOD">SOD</a>,
<a href="tbResList.php?qv=73&tsv=137&wNotes=on&word=GSH">GSH</a>
<a href="tbResList.php?qv=73&tsv=46&wNotes=on">Catalase</a>
<a href="tbResList.php?qv=73&tsv=597&wNotes=on">HO1</a>
<a href="tbResList.php?qv=73&wNotes=on&word=GPx">GPx</a>

 

- Raises
<a href="tbResList.php?qv=73&tsv=1103&wNotes=on&word=antiOx↑">AntiOxidant</a>
defense in Normal Cells:
<a href="tbResList.php?qv=73&tsv=275&wNotes=on&word=ROS↓">ROS↓</a>,
<a href="tbResList.php?qv=73&tsv=226&wNotes=on&word=NRF2↑">NRF2↑</a>,
<a href="tbResList.php?qv=73&tsv=298&wNotes=on&word=SOD↑">SOD↑</a>,
<a href="tbResList.php?qv=73&tsv=137&wNotes=on&word=GSH↑">GSH↑</a>,
<a href="tbResList.php?qv=73&tsv=46&wNotes=on&word=Catalase↑">Catalase↑</a>,
 


- lowers
<a href="tbResList.php?qv=73&tsv=953&wNotes=on&word=Inflam">Inflammation</a> :
<a href="tbResList.php?qv=73&tsv=214&wNotes=on&word=NF-kB↓">NF-kB↓</a>,
<a href="tbResList.php?qv=73&tsv=66&wNotes=on&word=COX2↓">COX2↓</a>,
<a href="tbResList.php?qv=73&tsv=235&wNotes=on&word=p38↓">p38↓</a>, Pro-Inflammatory Cytokines :
<a href="tbResList.php?qv=73&tsv=908&wNotes=on&word=NLRP3↓">NLRP3↓</a>,
<a href="tbResList.php?qv=73&tsv=978&wNotes=on&word=IL1β↓">IL-1β↓</a>,
<a href="tbResList.php?qv=73&tsv=309&wNotes=on&word=TNF-α↓">TNF-α↓</a>,
<a href="tbResList.php?qv=73&tsv=158&wNotes=on&word=IL6↓">IL-6↓</a>,
<a href="tbResList.php?qv=73&tsv=368&wNotes=on&word=IL8↓">IL-8↓</a>
 


- inhibit Growth/Metastases :
<a href="tbResList.php?qv=73&tsv=604&wNotes=on">TumMeta↓</a>,
<a href="tbResList.php?qv=73&tsv=323&wNotes=on">TumCG↓</a>,
<a href="tbResList.php?qv=73&tsv=96&wNotes=on">EMT↓</a>,
<a href="tbResList.php?qv=73&tsv=204&wNotes=on">MMPs↓</a>,
<a href="tbResList.php?qv=73&tsv=201&wNotes=on">MMP2↓</a>,
<a href="tbResList.php?qv=73&tsv=203&wNotes=on">MMP9↓</a>,

<a href="tbResList.php?qv=73&tsv=415&wNotes=on">IGF-1↓</a>,
<a href="tbResList.php?qv=73&tsv=428&wNotes=on">uPA↓</a>,
<a href="tbResList.php?qv=73&tsv=334&wNotes=on">VEGF↓</a>,

<a href="tbResList.php?qv=73&tsv=110&wNotes=on">FAK↓</a>,
<a href="tbResList.php?qv=73&tsv=273&wNotes=on">RhoA↓</a>,
<a href="tbResList.php?qv=73&tsv=214&wNotes=on">NF-κB↓</a>,


<a href="tbResList.php?qv=73&tsv=304&wNotes=on">TGF-β↓</a>,
<a href="tbResList.php?qv=73&tsv=719&wNotes=on">α-SMA↓</a>,
<a href="tbResList.php?qv=73&tsv=105&wNotes=on">ERK↓</a>

 


- reactivate genes thereby inhibiting cancer cell growth :
<a href="tbResList.php?qv=73&tsv=140&wNotes=on">HDAC↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=DNMT">DNMTs↓</a>,
<a href="tbResList.php?qv=73&tsv=108&wNotes=on">EZH2↓</a>,
<a href="tbResList.php?qv=73&tsv=236&wNotes=on">P53↑</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=HSP">HSP↓</a>,
<a href="tbResList.php?qv=73&tsv=506&wNotes=on">Sp proteins↓</a>,

 


- cause Cell cycle arrest :
<a href="tbResList.php?qv=73&tsv=322&wNotes=on">TumCCA↑</a>,
<a href="tbResList.php?qv=73&tsv=73&wNotes=on">cyclin D1↓</a>,
<a href="tbResList.php?qv=73&tsv=378&wNotes=on">cyclin E↓</a>,
<a href="tbResList.php?qv=73&tsv=467&wNotes=on">CDK2↓</a>,
<a href="tbResList.php?qv=73&tsv=894&wNotes=on">CDK4↓</a>,
<a href="tbResList.php?qv=73&tsv=895&wNotes=on">CDK6↓</a>,
 


- inhibits Migration/Invasion :
<a href="tbResList.php?qv=73&tsv=326&wNotes=on">TumCMig↓</a>,
<a href="tbResList.php?qv=73&tsv=324&wNotes=on">TumCI↓</a>,
<a href="tbResList.php?qv=73&tsv=309&wNotes=on&word=TNF-α↓">TNF-α↓</a>, 
<a href="tbResList.php?qv=73&tsv=110&wNotes=on">FAK↓</a>,
<a href="tbResList.php?qv=73&tsv=105&wNotes=on">ERK↓</a>,
<a href="tbResList.php?qv=73&tsv=96&wNotes=on">EMT↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=TOP">TOP1↓</a>,

 


- inhibits
<a href="tbResList.php?qv=73&tsv=129&wNotes=on">glycolysis</a>
/<a href="tbResList.php?qv=73&tsv=947&wNotes=on">Warburg Effect</a> and
<a href="tbResList.php?qv=73&tsv=21&wNotes=on&word=ATP↓">ATP depletion</a> :
<a href="tbResList.php?qv=73&tsv=143&wNotes=on">HIF-1α↓</a>,
<a href="tbResList.php?qv=73&tsv=772&wNotes=on">PKM2↓</a>,
<a href="tbResList.php?qv=73&tsv=35&wNotes=on">cMyc↓</a>,
<a href="tbResList.php?qv=73&tsv=566&wNotes=on&word=GLUT">GLUT1↓</a>,
<a href="tbResList.php?qv=73&tsv=906&wNotes=on">LDH↓</a>,
<a href="tbResList.php?qv=73&tsv=175&wNotes=on&word=LDH">LDHA↓</a>,
<a href="tbResList.php?qv=73&tsv=773&wNotes=on">HK2↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=PFK">PFKs↓</a>,

<a href="tbResList.php?qv=73&tsv=847&wNotes=on">ECAR↓</a>,
<a href="tbResList.php?qv=73&tsv=230&wNotes=on">OXPHOS↓</a>,
<a href="tbResList.php?qv=73&tsv=356&wNotes=on">GRP78↑</a>,
<a href="tbResList.php?qv=73&tsv=1278&wNotes=on">Glucose↓</a>,
<a href="tbResList.php?qv=73&tsv=623&wNotes=on">GlucoseCon↓</a>
 


- inhibits
<a href="tbResList.php?qv=73&tsv=447&wNotes=on">angiogenesis↓</a> :
<a href="tbResList.php?qv=73&tsv=334&wNotes=on">VEGF↓</a>,
<a href="tbResList.php?qv=73&tsv=143&wNotes=on">HIF-1α↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=NOTCH">Notch↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=FGF">FGF↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=PDGF">PDGF↓</a>,
<a href="tbResList.php?qv=73&tsv=94&wNotes=on&word=EGFR↓">EGFR↓</a>,
<a href="tbResList.php?qv=73&&wNotes=on&word=ITG">Integrins↓</a>,
 


- inhibits Cancer Stem Cells :
<a href="tbResList.php?qv=73&tsv=795&wNotes=on">CSC↓</a>,

<a href="tbResList.php?qv=73&tsv=141&wNotes=on">Hh↓</a>,
<a href="tbResList.php?qv=73&tsv=434&wNotes=on">GLi↓</a>,
<a href="tbResList.php?qv=73&tsv=124&wNotes=on">GLi1↓</a>,
<a href="tbResList.php?qv=73&tsv=677&wNotes=on">CD133↓</a>,
<a href="tbResList.php?qv=73&tsv=655&wNotes=on">CD24↓</a>,
<a href="tbResList.php?qv=73&tsv=342&wNotes=on">β-catenin↓</a>,
<a href="tbResList.php?qv=73&tsv=357&wNotes=on">n-myc↓</a>,

<a href="tbResList.php?qv=73&wNotes=on&word=NOTCH">Notch↓</a>,

<a href="tbResList.php?qv=73&tsv=508&wNotes=on">OCT4↓</a>,
 


- Others: <a href="tbResList.php?qv=73&tsv=252&wNotes=on">PI3K↓</a>,
<a href="tbResList.php?qv=73&tsv=4&wNotes=on">AKT↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=JAK">JAK↓</a>,
<a href="tbResList.php?qv=73&wNotes=on&word=STAT">STAT↓</a>,
<a href="tbResList.php?qv=73&tsv=377&wNotes=on">Wnt↓</a>,
<a href="tbResList.php?qv=73&tsv=342&wNotes=on">β-catenin↓</a>,
<a href="tbResList.php?qv=73&tsv=9&wNotes=on">AMPK</a>,

<a href="tbResList.php?qv=73&tsv=105&wNotes=on">ERK↓</a>,

<a href="tbResList.php?qv=73&tsv=168&wNotes=on">JNK</a>,

- <a href="tbResList.php?qv=73&wNotes=on&word=SREBP">SREBP</a> (related to cholesterol). 


- Synergies:
<a href="tbResList.php?qv=73&tsv=1106&wNotes=on">chemo-sensitization</a>,
<a href="tbResList.php?qv=73&tsv=1171&wNotes=on">chemoProtective</a>,
<a href="tbResList.php?qv=73&tsv=1107&wNotes=on">RadioSensitizer</a>,
<a href="tbResList.php?qv=73&tsv=1185&wNotes=on">RadioProtective</a>,
<a href="tbResList.php?qv=73&tsv=961&esv=2&wNotes=on&exSp=open">Others(review target notes)</a>,
<a href="tbResList.php?qv=73&tsv=1105&wNotes=on">Neuroprotective</a>,
<a href="tbResList.php?qv=73&tsv=557&wNotes=on">Cognitive</a>,
<a href="tbResList.php?qv=73&tsv=1175&wNotes=on">Renoprotection</a>,
<a href="tbResList.php?qv=73&tsv=1179&wNotes=on">Hepatoprotective</a>(possible damage at high dose),
<a href="tbResList.php?&qv=73&tsv=1188&wNotes=on">CardioProtective</a>,

 
 

- Selectivity:
<a href="tbResList.php?qv=73&tsv=1110&wNotes=on">Cancer Cells vs Normal Cells</a> 
 

<h3>EGCG Mechanistic Profile</h3>
<table border="1" cellspacing="0" cellpadding="4">
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Biphasic redox modulation</td>
<td>↑ ROS or ↓ ROS (dose-dependent) (context-dependent)</td>
<td>↓ ROS; ↑ antioxidant buffering</td>
<td>P–R</td>
<td>Oxidative stress or antioxidant protection</td>
<td>Auto-oxidation and metal-catalysed peroxide formation may drive cancer-cell toxicity; culture-medium oxidation can exaggerate this mechanism.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K AKT mTOR survival signalling</td>
<td>↓ PI3K; ↓ AKT; ↓ mTOR</td>
<td>↔ or adaptive modulation</td>
<td>R–G</td>
<td>Reduced proliferation and survival</td>
<td>Frequently reported across models, but direct target engagement at physiologically achievable concentrations remains uncertain.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial apoptosis</td>
<td>↓ ΔΨm; ↑ cytochrome c; ↑ caspase-9; ↑ caspase-3; ↑ PARP cleavage</td>
<td>↔ or preserved mitochondrial function</td>
<td>R–G</td>
<td>Intrinsic apoptotic death</td>
<td>Usually downstream of redox stress, calcium disturbance or survival-pathway inhibition.</td>
</tr>
<tr>
<td>4</td>
<td>NF-κB inflammatory survival signalling</td>
<td>↓ NF-κB; ↓ COX-2; ↓ inflammatory cytokines</td>
<td>↓ pathological inflammation</td>
<td>R–G</td>
<td>Reduced inflammatory and anti-apoptotic transcription</td>
<td>Potentially relevant to tumour-promoting inflammation and treatment resistance.</td>
</tr>
<tr>
<td>5</td>
<td>Cell-cycle regulation</td>
<td>↓ cyclin D1; ↓ cyclin E; ↓ CDK2; ↓ CDK4; ↓ CDK6; ↑ p21; ↑ arrest</td>
<td>↔ or transient arrest</td>
<td>G</td>
<td>Cytostatic growth inhibition</td>
<td>Arrest may occur at G1, S or G2/M depending on tumour type and concentration.</td>
</tr>
<tr>
<td>6</td>
<td>Invasion EMT and matrix remodelling</td>
<td>↓ EMT; ↓ FAK; ↓ uPA; ↓ MMP-2; ↓ MMP-9; ↓ migration</td>
<td>↔</td>
<td>G</td>
<td>Reduced invasion and metastatic phenotype</td>
<td>Predominantly supported by cellular and animal models.</td>
</tr>
<tr>
<td>7</td>
<td>HIF-1α VEGF angiogenesis axis</td>
<td>↓ HIF-1α; ↓ VEGF; ↓ angiogenic signalling</td>
<td>↔ or context-dependent vascular protection</td>
<td>G</td>
<td>Reduced hypoxia adaptation and angiogenesis</td>
<td>Responses depend on oxygen tension, cell type and exposure.</td>
</tr>
<tr>
<td>8</td>
<td>Glycolysis and energy metabolism</td>
<td>↓ GLUT1; ↓ HK2; ↓ PKM2; ↓ LDHA; ↓ ECAR; ↓ ATP (model-dependent)</td>
<td>↔ or improved metabolic homeostasis</td>
<td>R–G</td>
<td>Metabolic stress</td>
<td>Many metabolic findings use concentrations above typical human plasma exposure.</td>
</tr>
<tr>
<td>9</td>
<td>Calcium ER stress and proteostasis</td>
<td>↑ Ca²⁺; ↑ ER stress; ↑ UPR; ↑ GRP78 (context-dependent)</td>
<td>↔ or ↓ pathological ER stress</td>
<td>P–G</td>
<td>Proteotoxic stress and apoptosis</td>
<td>GRP78 and UPR activation may promote death or adaptation depending on intensity and duration.</td>
</tr>
<tr>
<td>10</td>
<td>Epigenetic regulation</td>
<td>↓ DNMT activity; ↓ HDAC signalling; ↓ EZH2 (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Re-expression of suppressed genes</td>
<td>Biochemical inhibition and intracellular effects may require different concentrations.</td>
</tr>
<tr>
<td>11</td>
<td>NRF2 antioxidant response</td>
<td>↑ NRF2 or ↔ (context-dependent)</td>
<td>↑ NRF2; ↑ HO-1; ↑ GSH; ↑ antioxidant enzymes</td>
<td>R–G</td>
<td>Secondary adaptive cytoprotection</td>
<td>NRF2 can protect normal tissue but may also counteract EGCG-induced oxidative injury or support resistant cancer cells.</td>
</tr>
<tr>
<td>12</td>
<td>Cancer stemness signalling</td>
<td>↓ Wnt β-catenin; ↓ Hedgehog GLI; ↓ Notch; ↓ stem-cell markers</td>
<td>↔</td>
<td>G</td>
<td>Reduced self-renewal phenotype</td>
<td>Evidence remains predominantly preclinical and model-dependent.</td>
</tr>
<tr>
<td>13</td>
<td>Chemosensitization</td>
<td>↑ treatment response or ↓ resistance (drug-dependent)</td>
<td>↔ or ↑ tissue protection</td>
<td>R–G</td>
<td>Adjunctive modulation</td>
<td>Reported with several cytotoxic and targeted agents, but EGCG can also alter drug absorption, transport or stability; combinations require individual evaluation.</td>
</tr>
<tr>
<td>14</td>
<td>Radiosensitization and radioprotection</td>
<td>↑ radiosensitivity or ↔ (schedule-dependent)</td>
<td>↓ radiation injury in some models</td>
<td>R–G</td>
<td>Context-dependent radiation modulation</td>
<td>Opposing tumour and normal-tissue effects are possible; clinical evidence is insufficient for routine supplementation during radiotherapy.</td>
</tr>
<tr>
<td>15</td>
<td>Clinical Translation Constraint</td>
<td>Effective experimental exposure often not systemically achievable</td>
<td>↑ hepatic risk with concentrated high-dose extracts</td>
<td>G</td>
<td>Limited clinical translation</td>
<td>Poor oral bioavailability, rapid metabolism, instability, formulation heterogeneity, fasting-related exposure, liver toxicity and limited definitive oncology trials constrain deployment.</td>
</tr>
</tbody>
</table>
P: 0–30 min    R: 30 min–3 hr    G: >3 hr

 
Alzheimer’s disease relevance: EGCG has substantial preclinical neuroprotective evidence but no established clinical efficacy for Alzheimer’s disease. Proposed actions include inhibition or remodelling of amyloid-β aggregation, altered amyloid precursor protein processing, metal chelation, reduced tau-associated injury, suppression of neuroinflammation, mitochondrial protection and activation of NRF2-associated antioxidant defences. Most positive findings derive from biochemical, cellular or animal models, and brain exposure after conventional oral administration is uncertain. EGCG should therefore be classified as preclinical or exploratory for Alzheimer’s disease rather than as a validated disease-modifying therapy.

<h3>EGCG in Alzheimer’s Disease</h3>
<table border="1" cellspacing="0" cellpadding="4">
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Amyloid beta aggregation</td>
<td>↓ fibril formation; ↑ non-toxic aggregate remodelling</td>
<td>Reduced amyloid-associated toxicity</td>
<td>Strong biochemical and preclinical rationale; effective brain exposure in humans remains uncertain.</td>
</tr>
<tr>
<td>2</td>
<td>Amyloid precursor protein processing</td>
<td>↑ non-amyloidogenic processing; ↓ amyloidogenic burden (model-dependent)</td>
<td>Reduced amyloid generation</td>
<td>Primarily demonstrated in cellular and animal systems.</td>
</tr>
<tr>
<td>3</td>
<td>Neuroinflammation</td>
<td>↓ NF-κB; ↓ NLRP3; ↓ inflammatory cytokines; ↓ microglial activation</td>
<td>Reduced inflammatory neurotoxicity</td>
<td>Inflammatory effects are context-, model- and dose-dependent.</td>
</tr>
<tr>
<td>4</td>
<td>Oxidative stress and NRF2</td>
<td>↓ ROS; ↑ NRF2; ↑ HO-1; ↑ endogenous antioxidant defence</td>
<td>Neuronal cytoprotection</td>
<td>Antioxidant signalling is more relevant at achievable exposure than many direct cytotoxic cancer mechanisms.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial function</td>
<td>↑ membrane stability; ↑ ATP preservation; ↓ mitochondrial ROS</td>
<td>Improved neuronal bioenergetics</td>
<td>Supported mainly by experimental injury and transgenic models.</td>
</tr>
<tr>
<td>6</td>
<td>Tau pathology</td>
<td>↓ tau phosphorylation or aggregation (model-dependent)</td>
<td>Reduced cytoskeletal and synaptic injury</td>
<td>Less developed evidence base than amyloid-related mechanisms.</td>
</tr>
<tr>
<td>7</td>
<td>Metal homeostasis</td>
<td>↓ redox-active iron and copper interactions</td>
<td>Reduced metal-promoted aggregation and oxidative injury</td>
<td>Chelation may contribute mechanistically but could also impair dietary non-heme iron absorption.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>↓ oral and brain exposure; ↑ formulation variability</td>
<td>Uncertain human efficacy</td>
<td>No convincing evidence currently establishes EGCG as an Alzheimer’s disease-modifying treatment.</td>
</tr>
</tbody>
</table>

Research papers

Year	Title	Authors	PMID	Link
2008	Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence	Harald Hoensch	PMC2703843	https://pmc.ncbi.nlm.nih.gov/articles/PMC2703843/
2015	Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells	Piwen Wang	PMC4166488	https://pmc.ncbi.nlm.nih.gov/articles/PMC4166488/
2017	Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review	Yingying Jiang	—	https://www.sciencedirect.com/science/article/abs/pii/S0045206817305849
2022	Contribution of Non-Coding RNAs to Anticancer Effects of Dietary Polyphenols: Chlorogenic Acid, Curcumin, Epigallocatechin-3-Gallate, Genistein, Quercetin and Resveratrol	Sumio Hayakawa	PMC9774417	https://pmc.ncbi.nlm.nih.gov/articles/PMC9774417/
2011	The anticancer flavonoid chrysin induces the unfolded protein response in hepatoma cells	Xiangming Sun	PMC3822950	https://pmc.ncbi.nlm.nih.gov/articles/PMC3822950/
2014	Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers	Guillermo Mariño	PMC4502795	https://pmc.ncbi.nlm.nih.gov/articles/PMC4502795/
2026	Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential	Ashok Kumar Sah	—	https://www.mdpi.com/2227-9059/14/1/215
2022	An update of Nrf2 activators and inhibitors in cancer prevention/promotion	Farhad Pouremamali	PMC9245222	https://pmc.ncbi.nlm.nih.gov/articles/PMC9245222/
2020	Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders	Zhibin Liang	PMC8084865	https://pmc.ncbi.nlm.nih.gov/articles/PMC8084865/
2015	Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling	Seyung S Chung	PMC4290892	https://pmc.ncbi.nlm.nih.gov/articles/PMC4290892/
2015	Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells	Dae-Woon Eom	PMC4576954	https://pmc.ncbi.nlm.nih.gov/articles/PMC4576954/
2011	Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation	Ammad Ahmad Farooqi	22070051	https://pubmed.ncbi.nlm.nih.gov/22070051/
2007	The effects of tetrahydrocurcumin and green tea polyphenol on the survival of male C57BL/6 mice	Kenichi Kitani	17516143	https://pubmed.ncbi.nlm.nih.gov/17516143/
2026	Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health	Li Niu	PMC12844721	https://pmc.ncbi.nlm.nih.gov/articles/PMC12844721/
2025	Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential	Lucia Capasso	—	https://www.researchgate.net/publication/388669154_Epigallocatechin_Gallate_EGCG_Pharmacological_Properties_Biological_Activities_and_Therapeutic_Potential
2025	A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation	Jin-jing He	PMC12497591	https://pmc.ncbi.nlm.nih.gov/articles/PMC12497591/
2025	Pharmacological and Genetic Approaches to Downregulate FIS1 Mitigate Neuropathic Pain	Chang-Lei Zhu	—	https://www.jneurosci.org/content/45/35/e0523252025
2025	The Role of ER Stress and the Unfolded Protein Response in Cancer	ROSE GHEMRAWI	—	https://cgp.iiarjournals.org/content/22/3/363
2025	Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential	Lucia Capasso	—	https://pmc.ncbi.nlm.nih.gov/articles/PMC11821029/
2025	Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy	Mohammad Qutub	—	https://link.springer.com/article/10.1208/s12249-025-03145-0
2024	Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway	Yinghui Wang	PMC11666909	https://pmc.ncbi.nlm.nih.gov/articles/PMC11666909/
2024	Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets	Wamidh H Talib	PMC10976257	https://pmc.ncbi.nlm.nih.gov/articles/PMC10976257/
2024	Absorption, metabolism, bioactivity, and biotransformation of epigallocatechin gallate	Shuling Zhang	36728926	https://pubmed.ncbi.nlm.nih.gov/36728926/
2024	The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review	Rupa Chaudhuri	38243984	https://pubmed.ncbi.nlm.nih.gov/38243984/
2024	EGCG inhibits diabetic nephrophathy through up regulation of PKM2	genomediscovery.org	—	https://genomediscovery.org/mmolecular-therapy-for-diabetic-nephropathy-dn-epigallocatechin-egcg-isolated-from-green-tea-increases-pyruvate-kinase-m2-pkm2-expression-decreases-toxic-glucose-metabolites-mitoc/
2024	Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial	Touchwin Petiwathayakorn	PMC11640449	https://pmc.ncbi.nlm.nih.gov/articles/PMC11640449/
2024	Immunomodulatory Effects of Green Tea Catechins and Their Ring Fission Metabolites in a Tumor Microenvironment Perspective	Emmanuele D S Andrade	PMC11478201	https://pmc.ncbi.nlm.nih.gov/articles/PMC11478201/
2024	Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment	Wenxue Sun	PMC11443569	https://pmc.ncbi.nlm.nih.gov/articles/PMC11443569/
2024	Chemoprophylaxis Effect of EGCG on the Recurrence of Colorectal Cancer: A Systematic Review and Meta-Analysis	Benyu He	38988171	https://pubmed.ncbi.nlm.nih.gov/38988171/
2024	EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway	Ho Woon Lee	—	https://www.sciencedirect.com/science/article/pii/S0167488924000028
2024	Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer	Shun Wang	—	https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03391-5
2023	Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns	Guichun Wang	—	https://cancerci.biomedcentral.com/articles/10.1186/s12935-023-03161-9
2023	Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs	Chunguang Wang	—	https://cancerci.biomedcentral.com/articles/10.1186/s12935-023-03081-8
2023	Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation	Yu Wang	—	https://www.researchgate.net/publication/370713821_Improving_the_anti-tumor_effect_of_EGCG_in_colorectal_cancer_cells_by_blocking_EGCG-induced_YAP_activation
2023	EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement	Amit Sehgal	—	https://www.sciencedirect.com/science/article/pii/S2667137923000255
2023	The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment	Víctor Marín	PMC10341956	https://pmc.ncbi.nlm.nih.gov/articles/PMC10341956/
2023	Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy	Gu Li	—	https://link.springer.com/article/10.1007/s11010-023-04768-2
2023	Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids	Md Soriful Islam	2023	https://www.nature.com/articles/s41598-023-35212-6
2023	Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review	Maha K A Khalifa	PMC11087435	https://pmc.ncbi.nlm.nih.gov/articles/PMC11087435/
2023	The Effects of Green Tea Catechins in Hematological Malignancies	Fernanda Isabel Della Via	PMC10385775	https://pmc.ncbi.nlm.nih.gov/articles/PMC10385775/
2023	Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies	Xin-Yu Wei	PMC10462709	https://pmc.ncbi.nlm.nih.gov/articles/PMC10462709/
2023	Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity	Hiroki Tanabe	—	https://pmc.ncbi.nlm.nih.gov/articles/PMC9862901/
2023	Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling	Sahily Rodriguez Torres	—	https://www.mdpi.com/2227-9059/11/4/1000
2023	Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications	Mateusz Kciuk	—	https://pmc.ncbi.nlm.nih.gov/articles/PMC10343677/pdf/molecules-28-05246.pdf
2023	An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers	Lee Siew-Keah	37328148	https://pubmed.ncbi.nlm.nih.gov/37328148/
2022	Antioxidation Function of EGCG by Activating Nrf2/HO-1 Pathway in Mice with Coronary Heart Disease	Xiaoyi Huang	PMC9293516	https://pmc.ncbi.nlm.nih.gov/articles/PMC9293516/
2022	Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro	Paul M Seidler	PMC9481533	https://pmc.ncbi.nlm.nih.gov/articles/PMC9481533/
2022	EGCG-coated silver nanoparticles self-assemble with selenium nanowires for treatment of drug-resistant bacterial infections by generating ROS and disrupting biofilms	Chenhao Yang	—	https://www.semanticscholar.org/paper/EGCG-coated-silver-nanoparticles-self-assemble-with-Yang-Wang/36ea7fc4cf689f9c6637599e8374ae35fdaef86f
2022	Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies	Asifa Khan	34176437	https://pubmed.ncbi.nlm.nih.gov/34176437/
2022	Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells	Phuriwat Khiewkamro	PMC9063442	https://pmc.ncbi.nlm.nih.gov/articles/PMC9063442/
2022	Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines	Fulvia Farabegoli	—	https://pubs.acs.org/doi/10.1021/acsomega.2c01829#
2022	Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface	Sheng-Chieh Hsu	PMC9330565	https://pmc.ncbi.nlm.nih.gov/articles/PMC9330565/
2022	When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy	Linna Yu	—	https://www.researchgate.net/publication/362395636_When_Natural_Compounds_Meet_Nanotechnology_Nature-Inspired_Nanomedicines_for_Cancer_Immunotherapy
2022	The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review	Elena Ferrari	—	https://www.researchgate.net/publication/360934968_The_Potential_of_Epigallocatechin_Gallate_EGCG_in_Targeting_Autophagy_for_Cancer_Treatment_A_Narrative_Review
2022	Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation	Ju Hyung Seok	PMC9523342	https://pmc.ncbi.nlm.nih.gov/articles/PMC9523342/
2022	Characterization of mesenchymal stem cells with augmented internalization of magnetic nanoparticles: The implication of therapeutic potential	Ching-Hui Chien	—	https://www.sciencedirect.com/science/article/abs/pii/S0304885322009453
2022	EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress	Wenbing Wu	—	https://onlinelibrary.wiley.com/doi/full/10.1155/2022/7099589
2021	Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations	Philippe-Henri Secretan	PMC8706847	https://pmc.ncbi.nlm.nih.gov/articles/PMC8706847/
2021	Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex	Omeima Abdullah	PMC8143546	https://pmc.ncbi.nlm.nih.gov/articles/PMC8143546/
2021	Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats	Shanji Nan	PMC8128347	https://pmc.ncbi.nlm.nih.gov/articles/PMC8128347/
2021	Flavonoids Targeting HIF-1: Implications on Cancer Metabolism	Marek Samec	PMC7794792	https://pmc.ncbi.nlm.nih.gov/articles/PMC7794792/
2020	Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways	Madhumitha Kedhari Sundaram	PMC7584697	https://pmc.ncbi.nlm.nih.gov/articles/PMC7584697/
2020	Prooxidant Effects of Epigallocatechin-3-Gallate in Health Benefits and Potential Adverse Effect	Jie Ouyang	PMC7441425	https://pmc.ncbi.nlm.nih.gov/articles/PMC7441425/
2020	Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK	Pan Jiang	PMC7595654	https://pmc.ncbi.nlm.nih.gov/articles/PMC7595654/
2020	Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer	Saleh A. Almatroodi	—	https://www.mdpi.com/1420-3049/25/14/3146
2020	Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells	Oskar Ciesielski	PMC7287656	https://pmc.ncbi.nlm.nih.gov/articles/PMC7287656/
2020	Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer	Mehdi Sharifi-Rad	—	https://www.researchgate.net/publication/338741198_Preclinical_Pharmacological_Activities_of_Epigallocatechin-3-gallate_in_Signaling_Pathways_An_Update_on_Cancer
2020	The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review	Shuang Zhang	32942205	https://pubmed.ncbi.nlm.nih.gov/32942205/
2020	Health Benefits and Chemical Composition of Matcha Green Tea: A Review	Joanna Kochman	PMC7796401	https://pmc.ncbi.nlm.nih.gov/articles/PMC7796401/
2020	Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes	Xiaoqing Chi	PMC7790551	https://pmc.ncbi.nlm.nih.gov/articles/PMC7790551/
2020	Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers	Vicente Andreu-Fernández	—	https://www.researchgate.net/publication/341598633_Bioavailability_of_Epigallocatechin_Gallate_Administered_With_Different_Nutritional_Strategies_in_Healthy_Volunteers
2020	Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells	Ling-Chun Yeh	—	https://www.sciencedirect.com/science/article/abs/pii/S0887233319306241
2020	Epigallocatechin Gallate (EGCG)		—	https://www.alzforum.org/therapeutics/epigallocatechin-gallate-egcg
2020	The Role of EGCG in Breast Cancer Prevention and Therapy	Adriana Romano	—	https://www.researchgate.net/publication/347873100_The_Role_of_EGCG_in_Breast_Cancer_Prevention_and_Therapy
2020	EGCG impedes human Tau aggregation and interacts with Tau	Shweta Kishor Sonawane	PMC7387440	https://pmc.ncbi.nlm.nih.gov/articles/PMC7387440/
2020	Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy	Kai Li	PMC7645157	https://pmc.ncbi.nlm.nih.gov/articles/PMC7645157/
2020	The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer	Linqi Yang	—	https://www.researchgate.net/publication/341133182_The_Epigenetic_Modification_of_Epigallocatechin_Gallate_EGCG_on_Cancer
2020	Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway	Bing-Huei Chen	—	https://www.nature.com/articles/s41598-020-62136-2
2020	Iron Chelation Properties of Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Analysis on Tfr/Fth Regulations and Molecular Docking	Zarith Nameyrra	—	https://www.researchgate.net/publication/340088640_Iron_Chelation_Properties_of_Green_Tea_Epigallocatechin-3-Gallate_EGCG_in_Colorectal_Cancer_Cells_Analysis_on_TfrFth_Regulations_and_Molecular_Docking
2020	Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice	Mohamed A Safwat	PMC7559993	https://pmc.ncbi.nlm.nih.gov/articles/PMC7559993/
2020	The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein	Cord Naujokat	—	https://www.researchgate.net/publication/339583519_The_Big_Five_Phytochemicals_Targeting_Cancer_Stem_Cells_Curcumin_EGCG_Sulforaphane_Resveratrol_and_Genistein
2020	The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas	Shuangshuang Zhang	PMC7504867	https://pmc.ncbi.nlm.nih.gov/articles/PMC7504867/
2019	Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways	Tingting Li	PMC6650192	https://pmc.ncbi.nlm.nih.gov/articles/PMC6650192/
2019	Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α	Zarith Nameyrra Md Nesra	—	https://www.researchgate.net/publication/338109917_Induction_of_Endoplasmic_Reticulum_Stress_Pathway_by_Green_Tea_Epigallocatechin-3-Gallate_EGCG_in_Colorectal_Cancer_Cells_Activation_of_PERKp-eIF2_a_ATF4_and_IRE1_a
2019	Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis	Hye Eun Lee	PMC6600669	https://pmc.ncbi.nlm.nih.gov/articles/PMC6600669/
2019	EGCG maintained Nrf2-mediated redox homeostasis and minimized etoposide resistance in lung cancer cells	Suchisnigdha	—	https://www.sciencedirect.com/science/article/abs/pii/S1756464619304773
2019	Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2α/ATF4 and IRE1α	Zarith Nameyrra Md Nesran	PMC6942794	https://pmc.ncbi.nlm.nih.gov/articles/PMC6942794/
2019	Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine	Ran Wei	—	https://www.researchgate.net/publication/335091666_Epigallocatechin-3-Gallate_EGCG_Suppresses_Pancreatic_Cancer_Cell_Growth_Invasion_and_Migration_partly_through_the_Inhibition_of_Akt_Pathway_and_Epithelial-Mesenchymal_Transition_Enhanced_Efficacy_whe
2019	Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts	Ran Wei	PMC6826788	https://pmc.ncbi.nlm.nih.gov/articles/PMC6826788/
2018	Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy	Tumenjin Enkhbat	30396944	https://pubmed.ncbi.nlm.nih.gov/30396944/
2018	Anti-fibrosis activity of combination therapy with epigallocatechin gallate, taurine and genistein by regulating glycolysis, gluconeogenesis, and ribosomal and lysosomal signaling pathways in HSC-T6 cells	Yan Li	PMC6257822	https://pmc.ncbi.nlm.nih.gov/articles/PMC6257822/
2018	(-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress	Simona Martinotti	29744892	https://pubmed.ncbi.nlm.nih.gov/29744892/
2018	Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling	Bakthavatchalam Velavan	—	https://www.sciencedirect.com/science/article/abs/pii/S0006291X18316073
2018	Evaluation of the neuroprotective effect of EGCG: a potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage	Ying Chen	30452052	https://pubmed.ncbi.nlm.nih.gov/30452052/
2018	EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells	Pan Jiang	30182373	https://pubmed.ncbi.nlm.nih.gov/30182373/
2018	Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth	Anchalee Rawangkan	PMC6222340	https://pmc.ncbi.nlm.nih.gov/articles/PMC6222340/
2018	(−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway	Sha Feng	PMC5920970	https://pmc.ncbi.nlm.nih.gov/articles/PMC5920970/
2018	Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways	Gloria Bonuccelli	PMC6128439	https://pmc.ncbi.nlm.nih.gov/articles/PMC6128439/
2018	The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate	Jiajun Zeng	PMC6225204	https://pmc.ncbi.nlm.nih.gov/articles/PMC6225204/
2018	Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway	Yongnan Li	29446047	https://pubmed.ncbi.nlm.nih.gov/29446047/
2018	Suppressive Effects of EGCG on Cervical Cancer	Ying-Qi Wang	—	https://www.researchgate.net/publication/327610816_Suppressive_Effects_of_EGCG_on_Cervical_Cancer
2018	Interaction of poly-l-lysine coating and heparan sulfate proteoglycan on magnetic nanoparticle uptake by tumor cells	Wei Xiong Siow	—	https://www.researchgate.net/publication/323871065_Interaction_of_poly-l-lysine_coating_and_heparan_sulfate_proteoglycan_on_magnetic_nanoparticle_uptake_by_tumor_cells
2018	Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models	Ran Wei	—	https://www.researchgate.net/publication/328236054_Suppressing_glucose_metabolism_with_epigallocatechin-3-gallate_EGCG_reduces_breast_cancer_cell_growth_in_preclinical_models
2018	Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea	Islam Rady	—	https://www.researchgate.net/publication/321911600_Cancer_preventive_and_therapeutic_effects_of_EGCG_the_major_polyphenol_in_green_tea
2018	Scientific opinion on the safety of green tea catechins	EFSA Panel on Food Additives	—	https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5239
2018	Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells	Hirota Fujiki	PMC5824026	https://pmc.ncbi.nlm.nih.gov/articles/PMC5824026/
2018	Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter	Gregory Haskin	PMC6380985	https://pmc.ncbi.nlm.nih.gov/articles/PMC6380985/
2018	Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer	Aide Negri	PMC6315581	https://pmc.ncbi.nlm.nih.gov/articles/PMC6315581/
2017	Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity	Juanjuan Wang	PMC5502302	https://pmc.ncbi.nlm.nih.gov/articles/PMC5502302/
2017	(-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease	Yufang Guo	28520620	https://pubmed.ncbi.nlm.nih.gov/28520620/
2017	Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1	Weixia Sun	28457936	https://pubmed.ncbi.nlm.nih.gov/28457936/
2017	Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration	Bose Karthikeyan	27778132	https://pubmed.ncbi.nlm.nih.gov/27778132/
2017	(−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway	Yue Chen	PMC5490551	https://pmc.ncbi.nlm.nih.gov/articles/PMC5490551/
2017	Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains	Feng Ye	PMC5473239	https://pmc.ncbi.nlm.nih.gov/articles/PMC5473239/
2017	Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate	Hirota Fujiki	PMC5693978	https://pmc.ncbi.nlm.nih.gov/articles/PMC5693978/
2017	Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke	Qian Bai	—	https://www.sciencedirect.com/science/article/abs/pii/S0166432816307872
2017	EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice	Mrinalini Tiwari	—	https://www.sciencedirect.com/science/article/abs/pii/S0753332216326695
2017	Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment	Hyung Joon Joo	PMC5943656	https://pmc.ncbi.nlm.nih.gov/articles/PMC5943656/
2017	Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines	Sohail Hussain	—	https://pmc.ncbi.nlm.nih.gov/articles/PMC5701581/
2017	A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells	Lin Zhao	—	https://www.nature.com/articles/cddis2017563
2016	Tea polyphenols EGCG and TF restrict tongue and liver carcinogenesis simultaneously induced by N-nitrosodiethylamine in mice	Subhayan Sur	27058323	https://pubmed.ncbi.nlm.nih.gov/27058323/
2016	Epigallocatechin gallate and mitochondria—A story of life and death	Marcos Roberto de Oliveira	—	https://www.sciencedirect.com/science/article/abs/pii/S1043661815301560
2016	Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells	Rattiyaporn Kanlaya	—	https://www.nature.com/articles/srep30233
2016	EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9	Ke-Wang Luo	—	https://www.researchgate.net/publication/311782892_EGCG_inhibited_bladder_cancer_SW780_cell_proliferation_and_migration_both_in_vitro_and_in_vivo_via_down_regulation_of_NF-kB_and_MMP-9
2016	Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer	Shusuke Toden	—	https://www.researchgate.net/publication/304940512_Epigallocatechin-3-gallate_targets_cancer_stem-like_cells_and_enhances_5-fluorouracil_chemosensitivity_in_colorectal_cancer
2016	In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity	Sainan Li	PMC4923908	https://pmc.ncbi.nlm.nih.gov/articles/PMC4923908/
2016	Anti-cancer effect of EGCG and its mechanisms	Motofumi Kumazoe	—	https://www.researchgate.net/publication/318469094_Anti-cancer_effect_of_EGCG_and_its_mechanisms
2016	Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy	Piwen Wang	—	https://www.researchgate.net/publication/301933430_Green_tea_and_quercetin_sensitize_PC-3_xenograft_prostate_tumors_to_docetaxel_chemotherapy
2015	EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism	Alice Modernelli	PMC4607952	https://pmc.ncbi.nlm.nih.gov/articles/PMC4607952/
2015	A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea	Dawn Lemanne, Keith I. Block	—	https://pmc.ncbi.nlm.nih.gov/articles/PMC4739749/pdf/cureus-0007-000000000441.pdf
2015	Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells	Xiaohua Pan	—	https://www.researchgate.net/publication/289992020_Estrogen_receptor-a36_is_involved_in_epigallocatechin-3-gallate_induced_growth_inhibition_of_ER-negative_breast_cancer_stemprogenitor_cells
2015	Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans	Nenad Naumovski	—	https://www.mdpi.com/2076-3921/4/2/373
2015	Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury	Pere Boadas-Vaello	PMC4625495	https://pmc.ncbi.nlm.nih.gov/articles/PMC4625495/
2015	A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea	Dawn Lemanne	—	https://glennsabin.com/wp-content/uploads/2016/01/Glenn_Sabin_Cureus_case_report.pdf
2015	Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals	Chuan LI	—	https://www.researchgate.net/publication/282316276_Biocompatible_and_biodegradable_nanoparticles_for_enhancement_of_anti-cancer_activities_of_phytochemicals
2015	(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression	Xiang Chang	25882496	https://pubmed.ncbi.nlm.nih.gov/25882496/
2015	Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate	Sabita N Saldanha	PMC4043227	https://pmc.ncbi.nlm.nih.gov/articles/PMC4043227/
2015	(−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression	Xiang Chang	—	https://www.sciencedirect.com/science/article/abs/pii/S0014482715001366
2015	Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis	Feng Gao	25591943	https://pubmed.ncbi.nlm.nih.gov/25591943/
2015	Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells	Qing-Yi Lu	PMC4523095	https://pmc.ncbi.nlm.nih.gov/articles/PMC4523095/
2015	(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells	Munawwar Ali Khan	25682960	https://pubmed.ncbi.nlm.nih.gov/25682960/
2014	The antimicrobial possibilities of green tea	Wanda C Reygaert	PMC4138486	https://pmc.ncbi.nlm.nih.gov/articles/PMC4138486/
2014	Green tea catechins potentiate the neuritogenic action of brain-derived neurotrophic factor: role of 67-kDa laminin receptor and hydrogen peroxide	Usha Gundimeda	24508265	https://pubmed.ncbi.nlm.nih.gov/24508265/
2014	Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity	Jingnan Zhang	24758520	https://pubmed.ncbi.nlm.nih.gov/24758520/
2014	Augmented cellular uptake of nanoparticles using tea catechins: effect of surface modification on nanoparticle-cell interaction	Yi-Ching Lu	25069428	https://pubmed.ncbi.nlm.nih.gov/25069428/
2014	Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)	Tait D Shanafelt	PMC3902473	https://pmc.ncbi.nlm.nih.gov/articles/PMC3902473/
2014	New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate	Hae-Suk Kim	PMC3909779	https://pmc.ncbi.nlm.nih.gov/articles/PMC3909779/
2014	Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84	Claudia Hanau	PMC3901999	https://pmc.ncbi.nlm.nih.gov/articles/PMC3901999/
2014	Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells	VONDINA R MOSELEY	PMC4017340	https://pmc.ncbi.nlm.nih.gov/articles/PMC4017340/
2014	Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications	Brahma N Singh	PMC4082721	https://pmc.ncbi.nlm.nih.gov/articles/PMC4082721/
2013	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics	Su-Ni Tang	PMC3480310	https://pmc.ncbi.nlm.nih.gov/articles/PMC3480310/
2013	Antioxidant effects of green tea	SARAH C FORESTER	PMC3679539	https://pmc.ncbi.nlm.nih.gov/articles/PMC3679539/
2013	(-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation	Murli Manohar	22959059	https://pubmed.ncbi.nlm.nih.gov/22959059/
2013	Epigallocatechin-3-gallate-capped Ag nanoparticles: preparation and characterization	Shokit Hussain	—	https://link.springer.com/article/10.1007/s00449-013-1094-0
2013	EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression	Jian-Wei Gu	PMC3649947	https://pmc.ncbi.nlm.nih.gov/articles/PMC3649947/
2013	Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy	Inyoung Kim	—	https://www.researchgate.net/publication/250926581_Targeting_the_AMP-Activated_Protein_Kinase_for_Cancer_Prevention_and_Therapy
2013	Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer	Zhiyu Wang	PMC3572989	https://pmc.ncbi.nlm.nih.gov/articles/PMC3572989/
2013	Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells	Di Chen	PMC3334407	https://pmc.ncbi.nlm.nih.gov/articles/PMC3334407/
2012	Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines	Chien-Hung Lin	PMC3575296	https://pmc.ncbi.nlm.nih.gov/articles/PMC3575296/
2012	Prevention effect of EGCG in rat's lung cancer induced by benzopyrene	Q.-X. Feng	—	https://www.researchgate.net/publication/287947721_Prevention_effect_of_EGCG_in_rat's_lung_cancer_induced_by_benzopyrene
2012	Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells	Piwen Wang	—	https://www.tandfonline.com/doi/abs/10.1080/01635581.2012.661514
2012	Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea	Guang-Jian Du	PMC3509513	https://pmc.ncbi.nlm.nih.gov/articles/PMC3509513/
2011	Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?	Derliz Mereles	PMC3189735	https://pmc.ncbi.nlm.nih.gov/articles/PMC3189735/
2011	Dietary Epicatechin Promotes Survival of Obese Diabetic Mice and Drosophila melanogaster	Hongwei Si	PMC3095141	https://pmc.ncbi.nlm.nih.gov/articles/PMC3095141/
2011	Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol	Lian-Ying Wu	—	https://www.sciencedirect.com/science/article/abs/pii/S0304416511000936
2011	Green tea constituents (−)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I– and topoisomerase II–DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide	Miguel López-Lázaro	—	https://academic.oup.com/mutage/article-abstract/26/4/489/1189168?redirectedFrom=fulltext&login=false
2010	The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention	Joshua D Lambert	PMC2946098	https://pmc.ncbi.nlm.nih.gov/articles/PMC2946098/
2010	Epigenetic targets of bioactive dietary components for cancer prevention and therapy	Syed M Meeran	PMC3024548	https://pmc.ncbi.nlm.nih.gov/articles/PMC3024548/
2010	Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells	Thomas De Luca	—	https://www.researchgate.net/publication/44644721_Reciprocal_Relationship_Between_Cytosolic_NADH_and_ENOX2_Inhibition_Triggers_Sphingolipid-Induced_Apoptosis_in_HeLa_Cells
2010	Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate	Huihui Zhang	20951799	https://pubmed.ncbi.nlm.nih.gov/20951799/
2010	(−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases	Omari J Bandele	PMC2893035	https://pmc.ncbi.nlm.nih.gov/articles/PMC2893035/
2010	Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer	Imtiaz A Siddiqui	—	https://www.researchgate.net/publication/49701530_Green_tea_polyphenol_EGCG_blunts_androgen_receptor_function_in_prostate_cancer
2010	(-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells	Guo-Qing Tang	20127255	https://pubmed.ncbi.nlm.nih.gov/20127255/
2009	Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin	Hsieh, T.-C	PMC3641843	https://pmc.ncbi.nlm.nih.gov/articles/PMC3641843/
2008	Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells	Anindita Agarwal	21479441	https://pubmed.ncbi.nlm.nih.gov/21479441/
2008	Dual Roles of Nrf2 in Cancer	Alexandria Lau	PMC2652397	https://pmc.ncbi.nlm.nih.gov/articles/PMC2652397/
2007	Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells	Hye-Young Shin	17135765	https://pubmed.ncbi.nlm.nih.gov/17135765/
2006	Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase	Changhong Li	16476731	https://pubmed.ncbi.nlm.nih.gov/16476731/
2005	Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells	Nobuhiko Higashi	15976760	https://pubmed.ncbi.nlm.nih.gov/15976760/
2005	EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells	Hye-Kyung Na	—	https://aacrjournals.org/cancerres/article/65/9_Supplement/367/519963/EGCG-upregulates-phase-2-detoxifying-and
2004	Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice	Joshua D Lambert	15284381	https://pubmed.ncbi.nlm.nih.gov/15284381/
2003	Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists	Renzo Deana	12719785	https://pubmed.ncbi.nlm.nih.gov/12719785/
2002	Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability	Mao-Jung Lee	12376503	https://pubmed.ncbi.nlm.nih.gov/12376503/
2002	Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H(2)O(2) at physiologically relevant EGCG concentrations	Wan-Mohaiza Dashwood	12176021	https://pubmed.ncbi.nlm.nih.gov/12176021/
2002	Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin	David Opare Kennedy	11880178	https://pubmed.ncbi.nlm.nih.gov/11880178/
2000	Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells	Fengge Ren	—	https://www.nature.com/articles/1203511
2000	Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture	D. James Morre´	—	—
2022	Targeting cancer stem cells by nutraceuticals for cancer therapy	Man Chu	—	https://www.sciencedirect.com/science/article/abs/pii/S1044579X21002029
2010	Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer	Anna Slusarz	20395211	https://pubmed.ncbi.nlm.nih.gov/20395211/
2012	Antiproliferative and Apoptotic Effects Triggered by Grape Seed Extract (GSE) versus Epigallocatechin and Procyanidins on Colon Cancer Cell Lines	Simona Dinicola	PMC3269711	https://pmc.ncbi.nlm.nih.gov/articles/PMC3269711/
2013	Plant polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: a mechanism for cancer chemopreventive action	Husain Yar Khan	24123728	https://pubmed.ncbi.nlm.nih.gov/24123728/
2020	Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer	Susanne M. Henning	—	https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo00565g
2013	Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea	Piwen Wang	PMC3858726	https://pmc.ncbi.nlm.nih.gov/articles/PMC3858726/
2010	The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition	Su-Ni Tang	PMC2933702	https://pmc.ncbi.nlm.nih.gov/articles/PMC2933702/
2010	The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition	Su-Ni Tang	—	https://link.springer.com/article/10.1186/1750-2187-5-14
2025	Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol	Mohamed Ahmed	PMC12225039	https://pmc.ncbi.nlm.nih.gov/articles/PMC12225039/
2010	Antithrombotic effects of naturally derived products on coagulation and platelet function	Shaker A Mousa	20617421	https://pubmed.ncbi.nlm.nih.gov/20617421/
2022	A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease	Sudhir Kshirsagar	PMC9454743	https://pmc.ncbi.nlm.nih.gov/articles/PMC9454743/
2022	A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease	Sudhir Kshirsagar	PMC9454743	https://pmc.ncbi.nlm.nih.gov/articles/PMC9454743/

Year

Title

Authors

PMID

Link

Flag

2008

Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence

Harald Hoensch

PMC2703843

https://pmc.ncbi.nlm.nih.gov/articles/PMC2703843/

2015

Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells

Piwen Wang

PMC4166488

https://pmc.ncbi.nlm.nih.gov/articles/PMC4166488/

2017

Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review

Yingying Jiang

—

https://www.sciencedirect.com/science/article/abs/pii/S0045206817305849

2022

Contribution of Non-Coding RNAs to Anticancer Effects of Dietary Polyphenols: Chlorogenic Acid, Curcumin, Epigallocatechin-3-Gallate, Genistein, Quercetin and Resveratrol

Sumio Hayakawa

PMC9774417

https://pmc.ncbi.nlm.nih.gov/articles/PMC9774417/

2011

The anticancer flavonoid chrysin induces the unfolded protein response in hepatoma cells

Xiangming Sun

PMC3822950

https://pmc.ncbi.nlm.nih.gov/articles/PMC3822950/

2014

Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers

Guillermo Mariño

PMC4502795

https://pmc.ncbi.nlm.nih.gov/articles/PMC4502795/

2026

Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential

Ashok Kumar Sah

—

https://www.mdpi.com/2227-9059/14/1/215

2022

An update of Nrf2 activators and inhibitors in cancer prevention/promotion

Farhad Pouremamali

PMC9245222

https://pmc.ncbi.nlm.nih.gov/articles/PMC9245222/

2020

Natural products targeting mitochondria: emerging therapeutics for age-associated neurological disorders

Zhibin Liang

PMC8084865

https://pmc.ncbi.nlm.nih.gov/articles/PMC8084865/

2015

Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling

Seyung S Chung

PMC4290892

https://pmc.ncbi.nlm.nih.gov/articles/PMC4290892/

2015

Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells

Dae-Woon Eom

PMC4576954

https://pmc.ncbi.nlm.nih.gov/articles/PMC4576954/

2011

Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation

Ammad Ahmad Farooqi

22070051

https://pubmed.ncbi.nlm.nih.gov/22070051/

2007

The effects of tetrahydrocurcumin and green tea polyphenol on the survival of male C57BL/6 mice

Kenichi Kitani

17516143

https://pubmed.ncbi.nlm.nih.gov/17516143/

2026

Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health

Li Niu

PMC12844721

https://pmc.ncbi.nlm.nih.gov/articles/PMC12844721/

2025

Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential

Lucia Capasso

—

https://www.researchgate.net/publication/388669154_Epigallocatechin_Gallate_EGCG_Pharmacological_Properties_Biological_Activities_and_Therapeutic_Potential

2025

A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation

Jin-jing He

PMC12497591

https://pmc.ncbi.nlm.nih.gov/articles/PMC12497591/

2025

Pharmacological and Genetic Approaches to Downregulate FIS1 Mitigate Neuropathic Pain

Chang-Lei Zhu

—

https://www.jneurosci.org/content/45/35/e0523252025

2025

The Role of ER Stress and the Unfolded Protein Response in Cancer

ROSE GHEMRAWI

—

https://cgp.iiarjournals.org/content/22/3/363

2025

Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential

Lucia Capasso

—

https://pmc.ncbi.nlm.nih.gov/articles/PMC11821029/

2025

Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy

Mohammad Qutub

—

https://link.springer.com/article/10.1208/s12249-025-03145-0

2024

Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway

Yinghui Wang

PMC11666909

https://pmc.ncbi.nlm.nih.gov/articles/PMC11666909/

2024

Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets

Wamidh H Talib

PMC10976257

https://pmc.ncbi.nlm.nih.gov/articles/PMC10976257/

2024

Absorption, metabolism, bioactivity, and biotransformation of epigallocatechin gallate

Shuling Zhang

36728926

https://pubmed.ncbi.nlm.nih.gov/36728926/

2024

The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review

Rupa Chaudhuri

38243984

https://pubmed.ncbi.nlm.nih.gov/38243984/

2024

EGCG inhibits diabetic nephrophathy through up regulation of PKM2

genomediscovery.org

—

https://genomediscovery.org/mmolecular-therapy-for-diabetic-nephropathy-dn-epigallocatechin-egcg-isolated-from-green-tea-increases-pyruvate-kinase-m2-pkm2-expression-decreases-toxic-glucose-metabolites-mitoc/

2024

Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial

Touchwin Petiwathayakorn

PMC11640449

https://pmc.ncbi.nlm.nih.gov/articles/PMC11640449/

2024

Immunomodulatory Effects of Green Tea Catechins and Their Ring Fission Metabolites in a Tumor Microenvironment Perspective

Emmanuele D S Andrade

PMC11478201

https://pmc.ncbi.nlm.nih.gov/articles/PMC11478201/

2024

Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment

Wenxue Sun

PMC11443569

https://pmc.ncbi.nlm.nih.gov/articles/PMC11443569/

2024

Chemoprophylaxis Effect of EGCG on the Recurrence of Colorectal Cancer: A Systematic Review and Meta-Analysis

Benyu He

38988171

https://pubmed.ncbi.nlm.nih.gov/38988171/

2024

EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway

Ho Woon Lee

—

https://www.sciencedirect.com/science/article/pii/S0167488924000028

2024

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

Shun Wang

—

https://cancerci.biomedcentral.com/articles/10.1186/s12935-024-03391-5

2023

Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns

Guichun Wang

—

https://cancerci.biomedcentral.com/articles/10.1186/s12935-023-03161-9

2023

Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs

Chunguang Wang

—

https://cancerci.biomedcentral.com/articles/10.1186/s12935-023-03081-8

2023

Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation

Yu Wang

—

https://www.researchgate.net/publication/370713821_Improving_the_anti-tumor_effect_of_EGCG_in_colorectal_cancer_cells_by_blocking_EGCG-induced_YAP_activation

2023

EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement

Amit Sehgal

—

https://www.sciencedirect.com/science/article/pii/S2667137923000255

2023

The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment

Víctor Marín

PMC10341956

https://pmc.ncbi.nlm.nih.gov/articles/PMC10341956/

2023

Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy

Gu Li

—

https://link.springer.com/article/10.1007/s11010-023-04768-2

2023

Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids

Md Soriful Islam

2023

https://www.nature.com/articles/s41598-023-35212-6

2023

Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review

Maha K A Khalifa

PMC11087435

https://pmc.ncbi.nlm.nih.gov/articles/PMC11087435/

2023

The Effects of Green Tea Catechins in Hematological Malignancies

Fernanda Isabel Della Via

PMC10385775

https://pmc.ncbi.nlm.nih.gov/articles/PMC10385775/

2023

Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies

Xin-Yu Wei

PMC10462709

https://pmc.ncbi.nlm.nih.gov/articles/PMC10462709/

2023

Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity

Hiroki Tanabe

—

https://pmc.ncbi.nlm.nih.gov/articles/PMC9862901/

2023

Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling

Sahily Rodriguez Torres

—

https://www.mdpi.com/2227-9059/11/4/1000

2023

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications

Mateusz Kciuk

—

https://pmc.ncbi.nlm.nih.gov/articles/PMC10343677/pdf/molecules-28-05246.pdf

2023

An Update on Impacts of Epigallocatechin Gallate Co-administration in Modulating Pharmacokinetics of Statins, Calcium Channel Blockers, and Beta-blockers

Lee Siew-Keah

37328148

https://pubmed.ncbi.nlm.nih.gov/37328148/

2022

Antioxidation Function of EGCG by Activating Nrf2/HO-1 Pathway in Mice with Coronary Heart Disease

Xiaoyi Huang

PMC9293516

https://pmc.ncbi.nlm.nih.gov/articles/PMC9293516/

2022

Structure-based discovery of small molecules that disaggregate Alzheimer’s disease tissue derived tau fibrils in vitro

Paul M Seidler

PMC9481533

https://pmc.ncbi.nlm.nih.gov/articles/PMC9481533/

2022

EGCG-coated silver nanoparticles self-assemble with selenium nanowires for treatment of drug-resistant bacterial infections by generating ROS and disrupting biofilms

Chenhao Yang

—

https://www.semanticscholar.org/paper/EGCG-coated-silver-nanoparticles-self-assemble-with-Yang-Wang/36ea7fc4cf689f9c6637599e8374ae35fdaef86f

2022

Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies

Asifa Khan

34176437

https://pubmed.ncbi.nlm.nih.gov/34176437/

2022

Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells

Phuriwat Khiewkamro

PMC9063442

https://pmc.ncbi.nlm.nih.gov/articles/PMC9063442/

2022

Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines

Fulvia Farabegoli

—

https://pubs.acs.org/doi/10.1021/acsomega.2c01829#

2022

Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface

Sheng-Chieh Hsu

PMC9330565

https://pmc.ncbi.nlm.nih.gov/articles/PMC9330565/

2022

When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

Linna Yu

—

https://www.researchgate.net/publication/362395636_When_Natural_Compounds_Meet_Nanotechnology_Nature-Inspired_Nanomedicines_for_Cancer_Immunotherapy

2022

The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review

Elena Ferrari

—

https://www.researchgate.net/publication/360934968_The_Potential_of_Epigallocatechin_Gallate_EGCG_in_Targeting_Autophagy_for_Cancer_Treatment_A_Narrative_Review

2022

Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation

Ju Hyung Seok

PMC9523342

https://pmc.ncbi.nlm.nih.gov/articles/PMC9523342/

2022

Characterization of mesenchymal stem cells with augmented internalization of magnetic nanoparticles: The implication of therapeutic potential

Ching-Hui Chien

—

https://www.sciencedirect.com/science/article/abs/pii/S0304885322009453

2022

EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress

Wenbing Wu

—

https://onlinelibrary.wiley.com/doi/full/10.1155/2022/7099589

2021

Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations

Philippe-Henri Secretan

PMC8706847

https://pmc.ncbi.nlm.nih.gov/articles/PMC8706847/

2021

Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex

Omeima Abdullah

PMC8143546

https://pmc.ncbi.nlm.nih.gov/articles/PMC8143546/

2021

Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats

Shanji Nan

PMC8128347

https://pmc.ncbi.nlm.nih.gov/articles/PMC8128347/

2021

Flavonoids Targeting HIF-1: Implications on Cancer Metabolism

Marek Samec

PMC7794792

https://pmc.ncbi.nlm.nih.gov/articles/PMC7794792/

2020

Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways

Madhumitha Kedhari Sundaram

PMC7584697

https://pmc.ncbi.nlm.nih.gov/articles/PMC7584697/

2020

Prooxidant Effects of Epigallocatechin-3-Gallate in Health Benefits and Potential Adverse Effect

Jie Ouyang

PMC7441425

https://pmc.ncbi.nlm.nih.gov/articles/PMC7441425/

2020

Epigallocatechin-3-gallate inhibits self-renewal ability of lung cancer stem-like cells through inhibition of CLOCK

Pan Jiang

PMC7595654

https://pmc.ncbi.nlm.nih.gov/articles/PMC7595654/

2020

Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer

Saleh A. Almatroodi

—

https://www.mdpi.com/1420-3049/25/14/3146

2020

Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells

Oskar Ciesielski

PMC7287656

https://pmc.ncbi.nlm.nih.gov/articles/PMC7287656/

2020

Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer

Mehdi Sharifi-Rad

—

https://www.researchgate.net/publication/338741198_Preclinical_Pharmacological_Activities_of_Epigallocatechin-3-gallate_in_Signaling_Pathways_An_Update_on_Cancer

2020

The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review

Shuang Zhang

32942205

https://pubmed.ncbi.nlm.nih.gov/32942205/

2020

Health Benefits and Chemical Composition of Matcha Green Tea: A Review

Joanna Kochman

PMC7796401

https://pmc.ncbi.nlm.nih.gov/articles/PMC7796401/

2020

Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes

Xiaoqing Chi

PMC7790551

https://pmc.ncbi.nlm.nih.gov/articles/PMC7790551/

2020

Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers

Vicente Andreu-Fernández

—

https://www.researchgate.net/publication/341598633_Bioavailability_of_Epigallocatechin_Gallate_Administered_With_Different_Nutritional_Strategies_in_Healthy_Volunteers

2020

Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells

Ling-Chun Yeh

—

https://www.sciencedirect.com/science/article/abs/pii/S0887233319306241

2020

Epigallocatechin Gallate (EGCG)

—

https://www.alzforum.org/therapeutics/epigallocatechin-gallate-egcg

2020

The Role of EGCG in Breast Cancer Prevention and Therapy

Adriana Romano

—

https://www.researchgate.net/publication/347873100_The_Role_of_EGCG_in_Breast_Cancer_Prevention_and_Therapy

2020

EGCG impedes human Tau aggregation and interacts with Tau

Shweta Kishor Sonawane

PMC7387440

https://pmc.ncbi.nlm.nih.gov/articles/PMC7387440/

2020

Advanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy

Kai Li

PMC7645157

https://pmc.ncbi.nlm.nih.gov/articles/PMC7645157/

2020

The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer

Linqi Yang

—

https://www.researchgate.net/publication/341133182_The_Epigenetic_Modification_of_Epigallocatechin_Gallate_EGCG_on_Cancer

2020

Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway

Bing-Huei Chen

—

https://www.nature.com/articles/s41598-020-62136-2

2020

Iron Chelation Properties of Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Analysis on Tfr/Fth Regulations and Molecular Docking

Zarith Nameyrra

—

https://www.researchgate.net/publication/340088640_Iron_Chelation_Properties_of_Green_Tea_Epigallocatechin-3-Gallate_EGCG_in_Colorectal_Cancer_Cells_Analysis_on_TfrFth_Regulations_and_Molecular_Docking

2020

Epigallocatechin-3-Gallate-Loaded Gold Nanoparticles: Preparation and Evaluation of Anticancer Efficacy in Ehrlich Tumor-Bearing Mice

Mohamed A Safwat

PMC7559993

https://pmc.ncbi.nlm.nih.gov/articles/PMC7559993/

2020

The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein

Cord Naujokat

—

https://www.researchgate.net/publication/339583519_The_Big_Five_Phytochemicals_Targeting_Cancer_Stem_Cells_Curcumin_EGCG_Sulforaphane_Resveratrol_and_Genistein

2020

The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas

Shuangshuang Zhang

PMC7504867

https://pmc.ncbi.nlm.nih.gov/articles/PMC7504867/

2019

Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways

Tingting Li

PMC6650192

https://pmc.ncbi.nlm.nih.gov/articles/PMC6650192/

2019

Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α

Zarith Nameyrra Md Nesra

—

https://www.researchgate.net/publication/338109917_Induction_of_Endoplasmic_Reticulum_Stress_Pathway_by_Green_Tea_Epigallocatechin-3-Gallate_EGCG_in_Colorectal_Cancer_Cells_Activation_of_PERKp-eIF2_a_ATF4_and_IRE1_a

2019

Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis

Hye Eun Lee

PMC6600669

https://pmc.ncbi.nlm.nih.gov/articles/PMC6600669/

2019

EGCG maintained Nrf2-mediated redox homeostasis and minimized etoposide resistance in lung cancer cells

Suchisnigdha

—

https://www.sciencedirect.com/science/article/abs/pii/S1756464619304773

2019

Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2α/ATF4 and IRE1α

Zarith Nameyrra Md Nesran

PMC6942794

https://pmc.ncbi.nlm.nih.gov/articles/PMC6942794/

2019

Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine

Ran Wei

—

https://www.researchgate.net/publication/335091666_Epigallocatechin-3-Gallate_EGCG_Suppresses_Pancreatic_Cancer_Cell_Growth_Invasion_and_Migration_partly_through_the_Inhibition_of_Akt_Pathway_and_Epithelial-Mesenchymal_Transition_Enhanced_Efficacy_whe

2019

Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts

Ran Wei

PMC6826788

https://pmc.ncbi.nlm.nih.gov/articles/PMC6826788/

2018

Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy

Tumenjin Enkhbat

30396944

https://pubmed.ncbi.nlm.nih.gov/30396944/

2018

Anti-fibrosis activity of combination therapy with epigallocatechin gallate, taurine and genistein by regulating glycolysis, gluconeogenesis, and ribosomal and lysosomal signaling pathways in HSC-T6 cells

Yan Li

PMC6257822

https://pmc.ncbi.nlm.nih.gov/articles/PMC6257822/

2018

(-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress

Simona Martinotti

29744892

https://pubmed.ncbi.nlm.nih.gov/29744892/

2018

Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling

Bakthavatchalam Velavan

—

https://www.sciencedirect.com/science/article/abs/pii/S0006291X18316073

2018

Evaluation of the neuroprotective effect of EGCG: a potential mechanism of mitochondrial dysfunction and mitochondrial dynamics after subarachnoid hemorrhage

Ying Chen

30452052

https://pubmed.ncbi.nlm.nih.gov/30452052/

2018

EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells

Pan Jiang

30182373

https://pubmed.ncbi.nlm.nih.gov/30182373/

2018

Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth

Anchalee Rawangkan

PMC6222340

https://pmc.ncbi.nlm.nih.gov/articles/PMC6222340/

2018

(−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway

Sha Feng

PMC5920970

https://pmc.ncbi.nlm.nih.gov/articles/PMC5920970/

2018

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways

Gloria Bonuccelli

PMC6128439

https://pmc.ncbi.nlm.nih.gov/articles/PMC6128439/

2018

The Effect of Ultrasound, Oxygen and Sunlight on the Stability of (−)-Epigallocatechin Gallate

Jiajun Zeng

PMC6225204

https://pmc.ncbi.nlm.nih.gov/articles/PMC6225204/

2018

Epigallocatechin gallate suppresses hepatic cholesterol synthesis by targeting SREBP-2 through SIRT1/FOXO1 signaling pathway

Yongnan Li

29446047

https://pubmed.ncbi.nlm.nih.gov/29446047/

2018

Suppressive Effects of EGCG on Cervical Cancer

Ying-Qi Wang

—

https://www.researchgate.net/publication/327610816_Suppressive_Effects_of_EGCG_on_Cervical_Cancer

2018

Interaction of poly-l-lysine coating and heparan sulfate proteoglycan on magnetic nanoparticle uptake by tumor cells

Wei Xiong Siow

—

https://www.researchgate.net/publication/323871065_Interaction_of_poly-l-lysine_coating_and_heparan_sulfate_proteoglycan_on_magnetic_nanoparticle_uptake_by_tumor_cells

2018

Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models

Ran Wei

—

https://www.researchgate.net/publication/328236054_Suppressing_glucose_metabolism_with_epigallocatechin-3-gallate_EGCG_reduces_breast_cancer_cell_growth_in_preclinical_models

2018

Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea

Islam Rady

—

https://www.researchgate.net/publication/321911600_Cancer_preventive_and_therapeutic_effects_of_EGCG_the_major_polyphenol_in_green_tea

2018

Scientific opinion on the safety of green tea catechins

EFSA Panel on Food Additives

—

https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5239

2018

Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells

Hirota Fujiki

PMC5824026

https://pmc.ncbi.nlm.nih.gov/articles/PMC5824026/

2018

Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter

Gregory Haskin

PMC6380985

https://pmc.ncbi.nlm.nih.gov/articles/PMC6380985/

2018

Molecular Targets of Epigallocatechin—Gallate (EGCG): A Special Focus on Signal Transduction and Cancer

Aide Negri

PMC6315581

https://pmc.ncbi.nlm.nih.gov/articles/PMC6315581/

2017

Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity

Juanjuan Wang

PMC5502302

https://pmc.ncbi.nlm.nih.gov/articles/PMC5502302/

2017

(-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer's disease

Yufang Guo

28520620

https://pubmed.ncbi.nlm.nih.gov/28520620/

2017

Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1

Weixia Sun

28457936

https://pubmed.ncbi.nlm.nih.gov/28457936/

2017

Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration

Bose Karthikeyan

27778132

https://pubmed.ncbi.nlm.nih.gov/27778132/

2017

(−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway

Yue Chen

PMC5490551

https://pmc.ncbi.nlm.nih.gov/articles/PMC5490551/

2017

Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains

Feng Ye

PMC5473239

https://pmc.ncbi.nlm.nih.gov/articles/PMC5473239/

2017

Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate

Hirota Fujiki

PMC5693978

https://pmc.ncbi.nlm.nih.gov/articles/PMC5693978/

2017

Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke

Qian Bai

—

https://www.sciencedirect.com/science/article/abs/pii/S0166432816307872

2017

EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice

Mrinalini Tiwari

—

https://www.sciencedirect.com/science/article/abs/pii/S0753332216326695

2017

Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment

Hyung Joon Joo

PMC5943656

https://pmc.ncbi.nlm.nih.gov/articles/PMC5943656/

2017

Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines

Sohail Hussain

—

https://pmc.ncbi.nlm.nih.gov/articles/PMC5701581/

2017

A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells

Lin Zhao

—

https://www.nature.com/articles/cddis2017563

2016

Tea polyphenols EGCG and TF restrict tongue and liver carcinogenesis simultaneously induced by N-nitrosodiethylamine in mice

Subhayan Sur

27058323

https://pubmed.ncbi.nlm.nih.gov/27058323/

2016

Epigallocatechin gallate and mitochondria—A story of life and death

Marcos Roberto de Oliveira

—

https://www.sciencedirect.com/science/article/abs/pii/S1043661815301560

2016

Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells

Rattiyaporn Kanlaya

—

https://www.nature.com/articles/srep30233

2016

EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9

Ke-Wang Luo

—

https://www.researchgate.net/publication/311782892_EGCG_inhibited_bladder_cancer_SW780_cell_proliferation_and_migration_both_in_vitro_and_in_vivo_via_down_regulation_of_NF-kB_and_MMP-9

2016

Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer

Shusuke Toden

—

https://www.researchgate.net/publication/304940512_Epigallocatechin-3-gallate_targets_cancer_stem-like_cells_and_enhances_5-fluorouracil_chemosensitivity_in_colorectal_cancer

2016

In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity

Sainan Li

PMC4923908

https://pmc.ncbi.nlm.nih.gov/articles/PMC4923908/

2016

Anti-cancer effect of EGCG and its mechanisms

Motofumi Kumazoe

—

https://www.researchgate.net/publication/318469094_Anti-cancer_effect_of_EGCG_and_its_mechanisms

2016

Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy

Piwen Wang

—

https://www.researchgate.net/publication/301933430_Green_tea_and_quercetin_sensitize_PC-3_xenograft_prostate_tumors_to_docetaxel_chemotherapy

2015

EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism

Alice Modernelli

PMC4607952

https://pmc.ncbi.nlm.nih.gov/articles/PMC4607952/

2015

A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea

Dawn Lemanne, Keith I. Block

—

https://pmc.ncbi.nlm.nih.gov/articles/PMC4739749/pdf/cureus-0007-000000000441.pdf

2015

Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells

Xiaohua Pan

—

https://www.researchgate.net/publication/289992020_Estrogen_receptor-a36_is_involved_in_epigallocatechin-3-gallate_induced_growth_inhibition_of_ER-negative_breast_cancer_stemprogenitor_cells

2015

Food Inhibits the Oral Bioavailability of the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans

Nenad Naumovski

—

https://www.mdpi.com/2076-3921/4/2/373

2015

Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury

Pere Boadas-Vaello

PMC4625495

https://pmc.ncbi.nlm.nih.gov/articles/PMC4625495/

2015

A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea

Dawn Lemanne

—

https://glennsabin.com/wp-content/uploads/2016/01/Glenn_Sabin_Cureus_case_report.pdf

2015

Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals

Chuan LI

—

https://www.researchgate.net/publication/282316276_Biocompatible_and_biodegradable_nanoparticles_for_enhancement_of_anti-cancer_activities_of_phytochemicals

2015

(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression

Xiang Chang

25882496

https://pubmed.ncbi.nlm.nih.gov/25882496/

2015

Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate

Sabita N Saldanha

PMC4043227

https://pmc.ncbi.nlm.nih.gov/articles/PMC4043227/

2015

(−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression

Xiang Chang

—

https://www.sciencedirect.com/science/article/abs/pii/S0014482715001366

2015

Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis

Feng Gao

25591943

https://pubmed.ncbi.nlm.nih.gov/25591943/

2015

Metabolic Consequences of LDHA inhibition by Epigallocatechin Gallate and Oxamate in MIA PaCa-2 Pancreatic Cancer Cells

Qing-Yi Lu

PMC4523095

https://pmc.ncbi.nlm.nih.gov/articles/PMC4523095/

2015

(-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells

Munawwar Ali Khan

25682960

https://pubmed.ncbi.nlm.nih.gov/25682960/

2014

The antimicrobial possibilities of green tea

Wanda C Reygaert

PMC4138486

https://pmc.ncbi.nlm.nih.gov/articles/PMC4138486/

2014

Green tea catechins potentiate the neuritogenic action of brain-derived neurotrophic factor: role of 67-kDa laminin receptor and hydrogen peroxide

Usha Gundimeda

24508265

https://pubmed.ncbi.nlm.nih.gov/24508265/

2014

Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity

Jingnan Zhang

24758520

https://pubmed.ncbi.nlm.nih.gov/24758520/

2014

Augmented cellular uptake of nanoparticles using tea catechins: effect of surface modification on nanoparticle-cell interaction

Yi-Ching Lu

25069428

https://pubmed.ncbi.nlm.nih.gov/25069428/

2014

Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)

Tait D Shanafelt

PMC3902473

https://pmc.ncbi.nlm.nih.gov/articles/PMC3902473/

2014

New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate

Hae-Suk Kim

PMC3909779

https://pmc.ncbi.nlm.nih.gov/articles/PMC3909779/

2014

Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84

Claudia Hanau

PMC3901999

https://pmc.ncbi.nlm.nih.gov/articles/PMC3901999/

2014

Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells

VONDINA R MOSELEY

PMC4017340

https://pmc.ncbi.nlm.nih.gov/articles/PMC4017340/

2014

Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications

Brahma N Singh

PMC4082721

https://pmc.ncbi.nlm.nih.gov/articles/PMC4082721/

2013

Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics

Su-Ni Tang

PMC3480310

https://pmc.ncbi.nlm.nih.gov/articles/PMC3480310/

2013

Antioxidant effects of green tea

SARAH C FORESTER

PMC3679539

https://pmc.ncbi.nlm.nih.gov/articles/PMC3679539/

2013

(-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation

Murli Manohar

22959059

https://pubmed.ncbi.nlm.nih.gov/22959059/

2013

Epigallocatechin-3-gallate-capped Ag nanoparticles: preparation and characterization

Shokit Hussain

—

https://link.springer.com/article/10.1007/s00449-013-1094-0

2013

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

Jian-Wei Gu

PMC3649947

https://pmc.ncbi.nlm.nih.gov/articles/PMC3649947/

2013

Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy

Inyoung Kim

—

https://www.researchgate.net/publication/250926581_Targeting_the_AMP-Activated_Protein_Kinase_for_Cancer_Prevention_and_Therapy

2013

Bioactivity-Guided Identification and Cell Signaling Technology to Delineate the Lactate Dehydrogenase A Inhibition Effects of Spatholobus suberectus on Breast Cancer

Zhiyu Wang

PMC3572989

https://pmc.ncbi.nlm.nih.gov/articles/PMC3572989/

2013

Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells

Di Chen

PMC3334407

https://pmc.ncbi.nlm.nih.gov/articles/PMC3334407/

2012

Epigallocathechin gallate, polyphenol present in green tea, inhibits stem-like characteristics and epithelial-mesenchymal transition in nasopharyngeal cancer cell lines

Chien-Hung Lin

PMC3575296

https://pmc.ncbi.nlm.nih.gov/articles/PMC3575296/

2012

Prevention effect of EGCG in rat's lung cancer induced by benzopyrene

Q.-X. Feng

—

https://www.researchgate.net/publication/287947721_Prevention_effect_of_EGCG_in_rat's_lung_cancer_induced_by_benzopyrene

2012

Quercetin Increased the Antiproliferative Activity of Green Tea Polyphenol (-)-Epigallocatechin Gallate in Prostate Cancer Cells

Piwen Wang

—

https://www.tandfonline.com/doi/abs/10.1080/01635581.2012.661514

2012

Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea

Guang-Jian Du

PMC3509513

https://pmc.ncbi.nlm.nih.gov/articles/PMC3509513/

2011

Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?

Derliz Mereles

PMC3189735

https://pmc.ncbi.nlm.nih.gov/articles/PMC3189735/

2011

Dietary Epicatechin Promotes Survival of Obese Diabetic Mice and Drosophila melanogaster

Hongwei Si

PMC3095141

https://pmc.ncbi.nlm.nih.gov/articles/PMC3095141/

2011

Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol

Lian-Ying Wu

—

https://www.sciencedirect.com/science/article/abs/pii/S0304416511000936

2011

Green tea constituents (−)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I– and topoisomerase II–DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide

Miguel López-Lázaro

—

https://academic.oup.com/mutage/article-abstract/26/4/489/1189168?redirectedFrom=fulltext&login=false

2010

The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention

Joshua D Lambert

PMC2946098

https://pmc.ncbi.nlm.nih.gov/articles/PMC2946098/

2010

Epigenetic targets of bioactive dietary components for cancer prevention and therapy

Syed M Meeran

PMC3024548

https://pmc.ncbi.nlm.nih.gov/articles/PMC3024548/

2010

Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells

Thomas De Luca

—

https://www.researchgate.net/publication/44644721_Reciprocal_Relationship_Between_Cytosolic_NADH_and_ENOX2_Inhibition_Triggers_Sphingolipid-Induced_Apoptosis_in_HeLa_Cells

2010

Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate

Huihui Zhang

20951799

https://pubmed.ncbi.nlm.nih.gov/20951799/

2010

(−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases

Omari J Bandele

PMC2893035

https://pmc.ncbi.nlm.nih.gov/articles/PMC2893035/

2010

Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer

Imtiaz A Siddiqui

—

https://www.researchgate.net/publication/49701530_Green_tea_polyphenol_EGCG_blunts_androgen_receptor_function_in_prostate_cancer

2010

(-)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells

Guo-Qing Tang

20127255

https://pubmed.ncbi.nlm.nih.gov/20127255/

2009

Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin

Hsieh, T.-C

PMC3641843

https://pmc.ncbi.nlm.nih.gov/articles/PMC3641843/

2008

Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells

Anindita Agarwal

21479441

https://pubmed.ncbi.nlm.nih.gov/21479441/

2008

Dual Roles of Nrf2 in Cancer

Alexandria Lau

PMC2652397

https://pmc.ncbi.nlm.nih.gov/articles/PMC2652397/

2007

Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells

Hye-Young Shin

17135765

https://pubmed.ncbi.nlm.nih.gov/17135765/

2006

Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase

Changhong Li

16476731

https://pubmed.ncbi.nlm.nih.gov/16476731/

2005

Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells

Nobuhiko Higashi

15976760

https://pubmed.ncbi.nlm.nih.gov/15976760/

2005

EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells

Hye-Kyung Na

—

https://aacrjournals.org/cancerres/article/65/9_Supplement/367/519963/EGCG-upregulates-phase-2-detoxifying-and

2004

Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice

Joshua D Lambert

15284381

https://pubmed.ncbi.nlm.nih.gov/15284381/

2003

Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists

Renzo Deana

12719785

https://pubmed.ncbi.nlm.nih.gov/12719785/

2002

Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability

Mao-Jung Lee

12376503

https://pubmed.ncbi.nlm.nih.gov/12376503/

2002

Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H(2)O(2) at physiologically relevant EGCG concentrations

Wan-Mohaiza Dashwood

12176021

https://pubmed.ncbi.nlm.nih.gov/12176021/

2002

Cellular thiol status-dependent inhibition of tumor cell growth via modulation of retinoblastoma protein phosphorylation by (-)-epigallocatechin

David Opare Kennedy

11880178

https://pubmed.ncbi.nlm.nih.gov/11880178/

2000

Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells

Fengge Ren

—

https://www.nature.com/articles/1203511

2000

Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture

D. James Morre´

—

2022

Targeting cancer stem cells by nutraceuticals for cancer therapy

Man Chu

—

https://www.sciencedirect.com/science/article/abs/pii/S1044579X21002029

2010

Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer

Anna Slusarz

20395211

https://pubmed.ncbi.nlm.nih.gov/20395211/

2012

Antiproliferative and Apoptotic Effects Triggered by Grape Seed Extract (GSE) versus Epigallocatechin and Procyanidins on Colon Cancer Cell Lines

Simona Dinicola

PMC3269711

https://pmc.ncbi.nlm.nih.gov/articles/PMC3269711/

2013

Plant polyphenol induced cell death in human cancer cells involves mobilization of intracellular copper ions and reactive oxygen species generation: a mechanism for cancer chemopreventive action

Husain Yar Khan

24123728

https://pubmed.ncbi.nlm.nih.gov/24123728/

2020

Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer

Susanne M. Henning

—

https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo00565g

2013

Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea

Piwen Wang

PMC3858726

https://pmc.ncbi.nlm.nih.gov/articles/PMC3858726/

2010

The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition

Su-Ni Tang

PMC2933702

https://pmc.ncbi.nlm.nih.gov/articles/PMC2933702/

2010

The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition

Su-Ni Tang

—

https://link.springer.com/article/10.1186/1750-2187-5-14

2025

Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol

Mohamed Ahmed

PMC12225039

https://pmc.ncbi.nlm.nih.gov/articles/PMC12225039/

2010

Antithrombotic effects of naturally derived products on coagulation and platelet function

Shaker A Mousa

20617421

https://pubmed.ncbi.nlm.nih.gov/20617421/

2022

A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease

Sudhir Kshirsagar

PMC9454743

https://pmc.ncbi.nlm.nih.gov/articles/PMC9454743/

2022

A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease

Sudhir Kshirsagar

PMC9454743

https://pmc.ncbi.nlm.nih.gov/articles/PMC9454743/

tbResList Print — EGCG EGCG (Epigallocatechin Gallate)

Product

Pathway results for Effect on Cancer / Diseased Cells

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Kinase & Signal Transduction(tgid=6) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Cellular Microenvironment(tgid=17) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Pathway results for Effect on Normal Cells

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Kinase & Signal Transduction(tgid=6) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Hormonal & Nuclear Receptors(tgid=20) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Research papers